IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.078
NA - Nord America 1.717
SA - Sud America 1.042
EU - Europa 324
AF - Africa 66
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.601
SG - Singapore 956
BR - Brasile 796
VN - Vietnam 624
CN - Cina 238
DE - Germania 119
AR - Argentina 108
IT - Italia 67
EC - Ecuador 53
ID - Indonesia 53
CA - Canada 50
BD - Bangladesh 41
HK - Hong Kong 38
MX - Messico 37
GB - Regno Unito 30
IN - India 30
FR - Francia 29
PY - Paraguay 25
CO - Colombia 20
IQ - Iraq 19
PL - Polonia 17
ZA - Sudafrica 17
CL - Cile 15
PK - Pakistan 13
RU - Federazione Russa 11
MA - Marocco 9
TN - Tunisia 9
AT - Austria 8
DZ - Algeria 8
EG - Egitto 8
JP - Giappone 8
PE - Perù 8
UA - Ucraina 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
VE - Venezuela 7
ES - Italia 6
FI - Finlandia 6
JO - Giordania 6
KE - Kenya 6
UZ - Uzbekistan 6
CR - Costa Rica 5
KZ - Kazakistan 5
MY - Malesia 5
TR - Turchia 5
HN - Honduras 4
JM - Giamaica 4
KG - Kirghizistan 4
NL - Olanda 4
GE - Georgia 3
KW - Kuwait 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
ET - Etiopia 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
NG - Nigeria 2
OM - Oman 2
PH - Filippine 2
SA - Arabia Saudita 2
SV - El Salvador 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AO - Angola 1
BH - Bahrain 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GH - Ghana 1
GN - Guinea 1
IE - Irlanda 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 5.232
Salva come PNG Salva come JPEG
Città #
Dallas 850
Singapore 249
Ho Chi Minh City 239
Ashburn 222
Hanoi 148
Beijing 115
Falkenstein 105
San Jose 105
São Paulo 65
New York 57
Los Angeles 51
Hong Kong 38
Rio de Janeiro 35
Santa Clara 34
Buffalo 30
Orem 29
Haiphong 24
Guayaquil 23
Assago 20
Biên Hòa 19
Curitiba 17
Da Nang 16
Mexico City 16
Warsaw 16
Charlotte 13
Montreal 13
Quito 13
Toronto 13
Asunción 12
Brasília 12
Hải Dương 12
Porto Alegre 12
London 11
Ninh Bình 11
Buenos Aires 10
Lấp Vò 10
Manaus 10
Salvador 10
Campinas 9
Chennai 9
Dhaka 9
Ha Long 9
Rome 9
Thái Bình 9
Bogotá 8
Guarulhos 8
Jundiaí 8
Osasco 8
Belo Horizonte 7
Cape Town 7
Fortaleza 7
Johannesburg 7
Maceió 7
Milan 7
Nova Iguaçu 7
Amman 6
Caracas 6
Denver 6
Helsinki 6
Jakarta 6
Lahore 6
Mumbai 6
Santiago 6
Santo André 6
Sumaré 6
Tashkent 6
Tokyo 6
Bauru 5
Blumenau 5
Córdoba 5
Manchester 5
Montevideo 5
Nairobi 5
Nanjing 5
North Kansas City 5
Nuremberg 5
Poplar 5
Quảng Ngãi 5
São Bernardo do Campo 5
Thái Nguyên 5
Tunis 5
Viamão 5
Aracaju 4
Baghdad 4
Barra Bonita 4
Belford Roxo 4
Birigui 4
Bishkek 4
Boston 4
Brooklyn 4
Bắc Ninh 4
Camaçari 4
Campo Grande 4
Chicago 4
Feira de Santana 4
Formosa 4
Frankfurt am Main 4
Goiânia 4
Houston 4
Imperatriz 4
Totale 3.039
Salva come PNG Salva come JPEG
Nome #
117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients. 568
Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer 68
New strategies to overcome BRAF resistance in melanoma: extended BRAF or BRAF/MEK inhibition? A pooled analysis. 66
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 63
Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 63
31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients 59
Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience. 57
Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis. 57
Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis. 55
55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 54
Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology. 52
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database 51
Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study. 51
Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. 49
Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis. 48
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC) 48
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance 47
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? 46
PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients. 46
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis 45
Treatment Toxicity 44
Baseline markers of inflammation and outcome with Nivolumab in pretreated Non Small Cell Lung Cancers: a retrospective study. 44
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study 43
Immune-Oncology Gene Expression Profiles allow lung cancer patients' stratification and identification of responders to immunotherapy. 43
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study 42
How I treat ALK-positive non-small cell lung cancer 40
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis. 39
Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy 38
A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection 38
Brave new world of cfDNA-omics for early cancer detection. 38
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. 37
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 37
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers. 37
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 36
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. 36
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP. 35
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 34
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 33
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer 33
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. 33
A Potentially New Targetable Alteration for the Treatment of Lung Cancer 33
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 33
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 33
A New Generation of Vaccines in the Age of Immunotherapy. 32
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer 32
Activity of EGFR tyrosine kinase inhibitors (TKIs) in brain metastases from Non Small Cell Lung Cancer (NSCLC) according to the EGFR mutational status: a survival analysis. 32
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. 31
Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer. 31
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. 31
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities 31
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care? 31
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. 30
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types 30
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 30
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 30
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 30
Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 30
Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non-Small-Cell Lung Cancer 29
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients. 29
Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies 29
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer 29
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study 29
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. 29
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 28
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 28
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 28
Acquired resistance in oncogene-addicted non-small-cell lung cancer 28
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA 28
Innovation in next-generation sequencing in non-small cell lung cancer diagnostics 28
Challenges of interpreting NGS liquid biopsy (LB) results in advanced NSCLC: Are ESCAT and OncoKB scales reliable? 28
Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients. 28
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. 28
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). 27
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 27
Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes. 27
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? 27
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 27
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. 27
Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: Management of C797S acquired mutation 26
Mechanisms of Resistance to first-line Osimertinib in Hispanic patients with EGFR mutant non-small cell lung cancer (FRESTON-CLICaP). 26
Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy. 26
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial 26
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion 26
NSCLC and HER2: between lights and shadows 26
Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives 26
The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution? 26
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1) 26
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. 25
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 25
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) 25
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. 25
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities. A commentary of the 3-year follow-up of the KEYNOTE-001 trial 25
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. 25
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. 25
Radiomic detection of EGFR mutations in NSCLC. 25
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. 25
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. 25
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. 25
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study 24
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 24
Totale 4.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.333
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.333
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20243 0 0 0 0 0 0 0 1 0 0 1 1
2024/20259 1 0 0 0 0 1 1 0 2 3 1 0
2025/20265.407 147 446 1.153 1.119 415 207 566 468 254 229 220 183
Totale 5.419